Literature DB >> 1341235

Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer.

E A Putnam1, N Yen, G E Gallick, P A Steck, K Fang, B Akpakip, A F Gazdar, J A Roth.   

Abstract

We studied the biological response to and production of transforming growth factor-alpha (TGF-alpha) by the non-small cell lung carcinoma (NSCLC) clonal cell lines H226b, H322a, H460a, H596b. Each of these cell lines expressed epidermal growth factor receptor (EGFR) as determined by [125I]EGF competitive binding and Scatchard analysis and by phosphorylation. The receptors were functionally active as determined in immune complex kinase assays. H322a, H226b, H460a, and H596b cells showed stimulated [3H]thymidine (Thd) uptake in response to TGF-alpha. Exogenously added TGF-alpha increased colony formation in soft agar for three of the cell lines in media containing serum. All cell lines expressed TGF-alpha detected by immunohistochemistry and TGF-alpha mRNA, although to differing degrees. Cell lysates and spent media competed for EGFR binding with EGF, thus demonstrating production of TGF-alpha-like activity. The anti-TGF-alpha monoclonal antibody AB-3 inhibited the uptake of [3H]Thd by proliferating H322a and H226b cells but not H460a and H596b cells. No inhibition occurred with MOPC21 antibody and inhibition was completely reversed by addition of TGF-alpha to the culture. Suramin inhibited cell proliferation and [3H]Thd uptake by all cell lines. Inhibition of H460a and H596b cells was reversed with exogenous TGF-alpha but not PDGF. Our data suggests that TGF-alpha is a mediator of autocrine growth stimulation for NSCLC cells, and that for some NSCLC cells cytoplasmic binding of receptor and ligand is the primary mechanism for autocrine growth stimulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341235     DOI: 10.1016/0960-7404(92)90056-q

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  6 in total

Review 1.  Novel insights into the molecular origins and treatment of lung cancer.

Authors:  James D Webb; M Celeste Simon
Journal:  Cell Cycle       Date:  2010-10-11       Impact factor: 4.534

2.  In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2.

Authors:  G Privitera; T Luca; N Musso; C Vancheri; N Crimi; V Barresi; D Condorelli; S Castorina
Journal:  Clin Exp Med       Date:  2015-02-26       Impact factor: 3.984

3.  Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.

Authors:  Hua Cheng; She-Juan An; Song Dong; Yi-Fang Zhang; Xu-Chao Zhang; Zhi-Hong Chen; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2011-01-21       Impact factor: 17.388

4.  Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.

Authors:  George Santis; Roger Angell; Guillermina Nickless; Alison Quinn; Amanda Herbert; Paul Cane; James Spicer; Ronan Breen; Emma McLean; Khalid Tobal
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

5.  Ion channels in hematopoietic and mesenchymal stem cells.

Authors:  Serena Pillozzi; Andrea Becchetti
Journal:  Stem Cells Int       Date:  2012-08-05       Impact factor: 5.443

6.  Simulating non-small cell lung cancer with a multiscale agent-based model.

Authors:  Zhihui Wang; Le Zhang; Jonathan Sagotsky; Thomas S Deisboeck
Journal:  Theor Biol Med Model       Date:  2007-12-21       Impact factor: 2.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.